SEARCH

SEARCH BY CITATION

References

  • 1
    Miller AB, Sankaranarayanan R, Bosch FX, Sepulveda C. Can screening for cervical cancer be improved, especially in developing countries? Int J Cancer 2003; 107: 33740.
  • 2
    Shi JF, Qiao YL, Smith JS, Dondog B, Bao YP, Dai M, Clifford GM, Franceschi S. Epidemiology and prevention of human papillomavirus and cervical cancer in China and Mongolia. Vaccine 2008; 26 ( Suppl 12): M53M59.
  • 3
    Zhao F, Li N, Ma J. Study of the association between human papillomavirus infection and cervical cancer in Xianguan county, Shanxi province. Zhonghua Liu Xing Bing Xue Za Zhi 2001; 22: 3758.
  • 4
    International Agency for Research on Cancer. Human papillomaviruses. IARC monographs on the evaluation of carcinogenic risks to humans, vol. 64. Lyon: International Agency for Research on Cancer, 1995. 409 p.
  • 5
    Alliance for Cervical Cancer Prevention (ACCP), 10 key findings and recommendations for effective cervical cancer screening and treatment programs. April 2007. Available at http://www.alliance-cxca.org/files/ACCP_recs_2007_factsheet_final.pdf
  • 6
    Goldie SJ, Gaffikin L, Goldhaber-Fiebert JD, Gordillo-Tobar A, Levin C, Mahe C, Wright TC; Alliance for Cervical Cancer Prevention Cost Working Group. Cost-effectiveness of cervical cancer screening in five developing countries. N Engl J Med 2005; 353: 215868.
  • 7
    Sankaranarayanan R, Nene BM, Shastri SS, Jayant K, Muwonge R, Budukh AM, Hingmire S, Malvi SG, Thorat R, Kothari A, Chinoy R, Kelkar R, et al. HPV screening for cervical cancer in rural India. N Engl J Med 2009; 360: 138594.
  • 8
    QIAGEN. Landmark study in New England Journal of Medicine shows HPV testing significantly reduces deaths from cervical cancer, compared to other methods including Pap. Press Release. April 1, 2009. Available at http://www1.qiagen.com/about/pressreleases/PressReleaseView.aspx?PressRelease ID=247
  • 9
    Gravitt PE, Coutlée F, Iftner T, Sellors JW, Quint WG, Wheeler CM. New technologies in cervical cancer screening. Vaccine 2008; 26 ( Suppl 10): K42K52.
  • 10
    Qiao YL, Sellors JW, Eder PS, Bao YP, Lim JM, Zhao FH, Weigl B, Zhang WH, Peck RB, Li L, Chen F, Pan QJ, et al. A new HPV-DNA test for cervical cancer screening in developing regions: a cross-sectional study of clinical accuracy in rural China. Lancet Oncol 2008; 9: 92936.
  • 11
    Jamison DT, Breman JG, Measham AR, Alleyne G, Claeson M, Evans D, Jha P, Mills A, Musgrove P. Disease control priorities in developing countries, 2nd edn. New York: Oxford University Press, 2006. 1401 p.
  • 12
    DrummondMF, SculpherMJ, TorranceGW, O'BrienBJ, StoddardtGL, eds. Methods for the economic evaluation of health care programs, 3rd edn. New York: Oxford University Press, 2005. 379 p.
  • 13
    GoldMR, SiegelJE, RussellLB, WeinsteinMC, eds. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996. 456 p.
  • 14
    World Health Organization (WHO), Statistical Information System. CHOICE (CHOosing Interventions that are Cost Effective). Available at http://www.who.int/choice/en/.
  • 15
    ZeyiC, eds. The guideline of treatment for common gynecological cancers, 2nd edn. Beijing: People's Health Publish House, 2007. 2340.
  • 16
    ZhiweiD, eds. The screening and early diagnosis of main cancers in China. The progress of cancer research in China, vol. 7. Beijing: Beijing University Medical Publish House, 2004. 21234.
  • 17
    Belinson J, Qiao YL, Pretorius R, Zhang WH, Elson P, Li L, Pan QJ, Fischer C, Lorincz A, Zahniser D. Shanxi Province Cervical Cancer Screening Study: a cross-sectional comparative trial of multiple techniques to detect cervical neoplasia. Gynecol Oncol 2001; 83: 43944. Erratum in: Gynecol Oncol 2002;84:355.
  • 18
    National Bureau of Statistics of China. China Statistical Yearbook, 2006. Available at http://www.stats.gov.cn/tjsj/ndsj/2006/indexch.htm.
  • 19
    Belinson JL, Qiao YL, Pretorius RG, Zhang WH, Rong SD, Huang MN, Zhao FH, Wu LY, Ren SD, Huang RD, Washington MF, Pan QJ, et al. Shanxi Province cervical cancer screening study II: self-sampling for high-risk human papillomavirus compared to direct sampling for human papillomavirus and liquid based cervical cytology. Int J Gynecol Cancer 2003; 13: 81926.
  • 20
    Mandelblatt JS, Lawrence WF, Gaffikin L, Limpahayom KK, Lumbiganon P, Warakamin S, King J, Yi B, Ringers P, Blumenthal PD. Costs and benefits of different strategies to screen for cervical cancer in less-developed countries. J Natl Cancer Inst 2002; 94: 146983.
  • 21
    Sankaranarayanan R, Gaffikin L, Jacob M, Sellors J, Robles S. A critical assessment of screening methods for cervical neoplasia. Int J Gynaecol Obstet 2005; 89 ( Suppl 2): S4S12.
  • 22
    World Health Organization (WHO), Department of Reproductive Health and Research. Mother-Baby Package Costing Spreadsheet Version 1.01. Geneva: WHO, 1999.
  • 23
    World Bank. World Development Indicators. Available at http://www.worldbank.org/data/onlinedatabases/onlinedatabases.html
  • 24
    Commission on Macroeconomics and Health. Macroeconomics and health: investing in health for economic development. Report of the commission on macroeconomics and health. Geneva: WHO, 2001.
  • 25
    Li N, Shi JF, Franceschi S, Zhang WH, Dai M, Liu B, Zhang YZ, Li LK, Wu RF, De Vuyst H, Plummer M, Qiao YL, et al. Different cervical cancer screening approaches in a Chinese multicentre study. Br J Cancer 2009; 100: 5327.
  • 26
    Schiller JT, Castellsagué X, Villa LL, Hildesheim A. An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results. Vaccine 2008; 26 ( Suppl 10): K53K61.
  • 27
    Shefer A, Markowitz L, Deeks S, Tam T, Irwin K, Garland SM, Schuchat A. Early experience with human papillomavirus vaccine introduction in the United States, Canada and Australia. Vaccine 2008; 26 ( Suppl 10): K68K75.
  • 28
    Garland SM, Cuzick J, Domingo EJ, Goldie SJ, Kim YT, Konno R, Parkin DM, Qiao YL, Sankaranarayanan R, Stern PL, Tay SK, Bosch FX. Recommendations for cervical cancer prevention in Asia Pacific. Vaccine 2008; 26 ( Suppl 12): M89M98.
  • 29
    Agosti JM, Goldie SJ. Introducing HPV vaccine in developing countries-key challenges and issues. N Engl J Med 2007; 356: 190810.
  • 30
    Goldie SJ, Diaz M, Kim SY, Levin CE, van Minh H, Kim JJ. Mathematical models of cervical cancer prevention in the Asia Pacific region. Vaccine 2008; 26 ( Suppl 12): M17M29.
  • 31
    Goldie SJ, O'Shea M, Campos NG, Diaz M, Sweet S, Kim SY. Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries. Vaccine 2008; 26: 408093.
  • 32
    Goldie SJ, O'Shea M, Diaz M, Kim SY. Benefits, cost requirements and cost-effectiveness of the HPV16,18 vaccine for cervical cancer prevention in developing countries: policy implications. Reprod Health Matters 2008; 16: 8696.
  • 33
    Tsu V, Levin CE. Making the case for cervical cancer prevention: what about equity? Reprod Health Matters 2008; 16: 10412.
  • 34
    Wang H, Xu T, Xu J. Factors contributing to high costs and inequality in China's health care system. JAMA 2007; 298: 192833.